title: Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer.
abstract: BACKGROUND
  Pancreatic cancer is the fifth leading cause of cancer-related death worldwide. Among patients treated with surgery alone, liver metastasis occurs in up to 50%, peritoneal recurrence in 25%, and local recurrence occurs in 50-80% of all patients who underwent resection. Even after a macroscopically curative resection, tumour cells might be observed by microscopy at one or more edges of the resected specimen in 20-51% (R-1) which might account for the high local recurrence.
  
  
  OBJECTIVE
  An analysis was performed in 54 patients who underwent an irradical resection (R-1 and R-2) for pancreatic cancer. 33 patients were treated with chemoradiotherapy. To evaluate the effect of therapy on survival and recurrence, this group was retrospectively compared to a group of 21 patients that did not receive chemoradiotherapy.
  
  
  METHODS
  Radiotherapy consisted of 50 Gy external upper abdomen radiation in two courses of 3 weeks, concomitant with intravenous 5-FU 25 mg/kg/24 h continuously on the first 4 days of each treatment course. Follow-up was performed mainly by CT scanning and occasionally by US and was completed for all but 1 patient.
  
  
  RESULTS
  The treatment protocol was completed in all patients without complications. Local recurrence was found in 6 (18%) patients in the group of patients who received adjuvant therapy versus 16 (48%) patients in the group that did not receive adjuvant therapy (p = 0.001). The median survival time for the treated group was 12.8 vs. 13.7 months in the group that did not receive chemoradiotherapy (p = 0.9). Three (9%) patients are still alive 140, 88 and 70 months after receiving surgery and adjuvant treatment.
  
  
  CONCLUSIONS
  Adjuvant chemoradiotherapy clearly gives a significant better local control. However, treatment with 5-FU and radiotherapy does not improve survival due to distant metastases. This therapy probably prolongs survival in only a few patients. More effective treatment methods have to be designed to prevent metastatic disease and improve survival.
authors.affiliation: Department of Surgery, Dijkzigt University Hospital, Rotterdam, The Netherlands.
authors.forename: Hans G
authors.initials: HG
authors.lastname: Smeenk
authors.forename: Luca
authors.initials: L
authors.lastname: Incrocci
authors.forename: Geert
authors.initials: G
authors.lastname: Kazemier
authors.forename: Herman
authors.initials: H
authors.lastname: van Dekken
authors.forename: Khe T C
authors.initials: KT
authors.lastname: Tran
authors.forename: Johannes
authors.initials: J
authors.lastname: Jeekel
authors.forename: Casper H J
authors.initials: CH
authors.lastname: van Eijck
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D005472:Fluorouracil